Amiloride

CHEMBL945 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
229.6 g/mol
LogP
-0.7
Phase
4

A potassium-sparing diuretic that blocks sodium channels in the kidney tubules, reducing sodium reabsorption and water retention without causing the potassium loss associated with most other diuretics. It is used to treat high blood pressure and fluid overload, often combined with potassium-wasting diuretics to maintain normal potassium levels.

น้ำหนักโมเลกุล

229.6300 g/mol

LogP

-0.70

TPSA

159.00 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

N=C(N)NC(=O)c1nc(Cl)c(N)nc1N

InChI

InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15)

Molecular Formula

C6H8ClN7O

HBD / HBA

4 / 5

พันธะที่หมุนได้

1

อะตอมหนัก

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A potassium-sparing diuretic that blocks sodium channels in the kidney tubules, reducing sodium reabsorption and water retention without causing the potassium loss associated with most other diuretics. It is used to treat high blood pressure and fluid overload, often combined with potassium-wasting diuretics to maintain normal potassium levels.

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Yes, Amiloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL945. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 16231. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.